A novel class of anti-cancer agents designed and optimized to target the microtubule destabilizing protein Stathmin. The agents are chalcone derivatives of indole-tetralone that block STMN1 phosphorylation leading to STMN1 accumulation and mitotic catastrophe resulting in cell death, and reduced cell proliferation.
• Targeting stathmin pathway provides enhanced efficacy as cancer cells in different cell cycle phases are targeted
• Potential to block metastasis demonstrated in vitro
• Potential for efficacy against drug-resistant tumors demonstrated in vitro
Efficacy against prostate, lung and pancreatic cancer demonstrated in vitro
Stage of Development
In vitro cell lines for prostate, lung and pancreatic cancer and paclitaxel-induced drug-resistant cell lines
Available for licensing and research collaboration